6g2s: Difference between revisions
No edit summary |
No edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Crystal structure of FimH in complex with a pentaflourinated biphenyl alpha D-mannoside== | |||
<StructureSection load='6g2s' size='340' side='right'caption='[[6g2s]], [[Resolution|resolution]] 2.20Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[6g2s]] is a 9 chain structure with sequence from [http://en.wikipedia.org/wiki/Ecoli Ecoli]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6G2S OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6G2S FirstGlance]. <br> | |||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=EJN:(2~{R},3~{S},4~{S},5~{S},6~{R})-2-(hydroxymethyl)-6-[4-[2,3,4,5,6-pentakis(fluoranyl)phenyl]phenoxy]oxane-3,4,5-triol'>EJN</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr> | |||
<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">fimH, b4320, JW4283 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=83333 ECOLI])</td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6g2s FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6g2s OCA], [http://pdbe.org/6g2s PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6g2s RCSB], [http://www.ebi.ac.uk/pdbsum/6g2s PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6g2s ProSAT]</span></td></tr> | |||
</table> | |||
== Function == | |||
[[http://www.uniprot.org/uniprot/FIMH_ECOLI FIMH_ECOLI]] Involved in regulation of length and mediation of adhesion of type 1 fimbriae (but not necessary for the production of fimbriae). Adhesin responsible for the binding to D-mannose. It is laterally positioned at intervals in the structure of the type 1 fimbriae. In order to integrate FimH in the fimbriae FimF and FimG are needed. | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
Antimicrobial resistance has become a serious concern for the treatment of urinary tract infections. In this context, an anti-adhesive approach targeting FimH, a bacterial lectin enabling the attachment of E. coli to host cells, has attracted considerable interest. FimH can adopt a low/medium-affinity state in the absence and a high-affinity state in the presence of shear forces. Until recently, mostly the high-affinity state has been investigated, despite the fact that a therapeutic antagonist should bind predominantly to the low-affinity state. In this communication, we demonstrate that fluorination of biphenyl alpha-d-mannosides leads to compounds with perfect pi-pi stacking interactions with the tyrosine gate of FimH, yielding low nanomolar to sub-nanomolar KD values for the low- and high-affinity states, respectively. The face-to-face alignment of the perfluorinated biphenyl group of FimH ligands and Tyr48 was confirmed by crystal structures as well as (1) H,(15) N-HSQC NMR analysis. Finally, fluorination improves pharmacokinetic parameters predictive for oral availability. | |||
Improvement of Aglycone pi-Stacking Yields Nanomolar to Sub-nanomolar FimH Antagonists.,Schonemann W, Cramer J, Muhlethaler T, Fiege B, Silbermann M, Rabbani S, Datwyler P, Zihlmann P, Jakob RP, Sager CP, Smiesko M, Schwardt O, Maier T, Ernst B ChemMedChem. 2019 Feb 1. doi: 10.1002/cmdc.201900051. PMID:30710416<ref>PMID:30710416</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
[[Category: | </div> | ||
<div class="pdbe-citations 6g2s" style="background-color:#fffaf0;"></div> | |||
== References == | |||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: Ecoli]] | |||
[[Category: Large Structures]] | |||
[[Category: Cramer, J]] | |||
[[Category: Daetwyler, P]] | |||
[[Category: Eris, D]] | |||
[[Category: Ernst, B]] | |||
[[Category: Fiege, B]] | |||
[[Category: Jakob, R P]] | |||
[[Category: Maier, T]] | |||
[[Category: Muehlethaler, T]] | |||
[[Category: Rabbani, S]] | |||
[[Category: Sager, C P]] | |||
[[Category: Schoenemann, W]] | |||
[[Category: Schwardt, O]] | |||
[[Category: Smiesko, M]] | |||
[[Category: Zihlmann, P]] | |||
[[Category: Catch-bond]] | |||
[[Category: Cell adhesion]] | |||
[[Category: Infection]] | |||
[[Category: Lectin]] | |||
[[Category: Mannose]] | |||
[[Category: Type i pilus]] | |||
[[Category: Upec]] | |||
Latest revision as of 09:48, 17 April 2019
Crystal structure of FimH in complex with a pentaflourinated biphenyl alpha D-mannosideCrystal structure of FimH in complex with a pentaflourinated biphenyl alpha D-mannoside
Structural highlights
Function[FIMH_ECOLI] Involved in regulation of length and mediation of adhesion of type 1 fimbriae (but not necessary for the production of fimbriae). Adhesin responsible for the binding to D-mannose. It is laterally positioned at intervals in the structure of the type 1 fimbriae. In order to integrate FimH in the fimbriae FimF and FimG are needed. Publication Abstract from PubMedAntimicrobial resistance has become a serious concern for the treatment of urinary tract infections. In this context, an anti-adhesive approach targeting FimH, a bacterial lectin enabling the attachment of E. coli to host cells, has attracted considerable interest. FimH can adopt a low/medium-affinity state in the absence and a high-affinity state in the presence of shear forces. Until recently, mostly the high-affinity state has been investigated, despite the fact that a therapeutic antagonist should bind predominantly to the low-affinity state. In this communication, we demonstrate that fluorination of biphenyl alpha-d-mannosides leads to compounds with perfect pi-pi stacking interactions with the tyrosine gate of FimH, yielding low nanomolar to sub-nanomolar KD values for the low- and high-affinity states, respectively. The face-to-face alignment of the perfluorinated biphenyl group of FimH ligands and Tyr48 was confirmed by crystal structures as well as (1) H,(15) N-HSQC NMR analysis. Finally, fluorination improves pharmacokinetic parameters predictive for oral availability. Improvement of Aglycone pi-Stacking Yields Nanomolar to Sub-nanomolar FimH Antagonists.,Schonemann W, Cramer J, Muhlethaler T, Fiege B, Silbermann M, Rabbani S, Datwyler P, Zihlmann P, Jakob RP, Sager CP, Smiesko M, Schwardt O, Maier T, Ernst B ChemMedChem. 2019 Feb 1. doi: 10.1002/cmdc.201900051. PMID:30710416[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
| ||||||||||||||||||